Article
Steroid-resistant nephrotic syndrome: pharmacogenetics and epigenetic points and views.
Expert review of clinical pharmacology - 1 Feb 2020
Hejazian Seyede Mina, Zununi Vahed Sepideh, Moghaddas Sani Hakimeh, Nariman-Saleh-Fam Ziba, Bastami Milad, Hosseiniyan Khatibi Seyed Mahdi, Ardalan Mohammadreza, Samadi Nasser
Abstract excerpt
Introduction: Glucocorticoids (GCs) are the first-line therapy for patients with nephrotic syndrome (NS), a common glomerular disease, that cause complete remission in most of the cases. In response to the treatment, NS patients are divided into glucocorticoid-sensitive and -resistant. This variation is due to the differences in pharmacokinetics and pharmacodynamics of GCs in each patient that affect the response...
Read the complete abstract on PubMedTopics
Share this publication in a Topic to start or enrich a Post.